C1 inhibitor mitigates peritoneal injury in zymosan-induced peritonitis

Am J Physiol Renal Physiol. 2021 Jun 1;320(6):F1123-F1132. doi: 10.1152/ajprenal.00600.2020. Epub 2021 Apr 5.

Abstract

Peritonitis, due to a fungal or bacterial infection, leads to injury of the peritoneal lining and thereby forms a hazard for the long-term success of peritoneal dialysis (PD) and remains a lethal complication in patients with PD. This study investigated whether C1 inhibitor (C1-INH) could protect against the progression of peritoneal injuries with five daily administrations of zymosan after mechanical scraping of the rat peritoneum to mimic fungal peritonitis. Severe peritoneal injuries were seen in this model, accompanied by fibrinogen/fibrin exudation and peritoneal deposition of complement activation products such as activated C3 and C5b-9. However, intraperitoneal injection of C1-INH decreased peritoneal depositions of activated C3 and C5b-9, ameliorated peritoneal thickening, reduced the influx of inflammatory cells, and prevented the production of peritoneal fibrous layers with both one and two doses of C1-INH each day. Our results suggest that C1-INH might be useful to protect against peritoneal injuries after causes of peritonitis such as fungal infection. This clinically available agent may thus help extend the duration of PD.NEW & NOTEWORTHY Peritoneal injuries associated with peritonitis comprise an important issue to prevent long-term peritoneal dialysis (PD) therapy. Here, we showed that C1 inhibitor (C1-INH), as an anticomplement agent, protected against peritoneal injuries in a peritonitis animal model related to fungal infection. Therefore, C1-INH might be useful to protect against peritoneal injuries after peritonitis due to fungal infection. This clinically available agent may thus help extend the duration of PD.

Keywords: C1 inhibitor; complement; peritoneal dialysis; peritoneal injuries; peritonitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Complement C1 Inhibitor Protein / therapeutic use*
  • Epithelial Cells
  • Epithelium
  • Fibrin / metabolism
  • Fibrinogen / metabolism
  • Male
  • Peritoneum / cytology
  • Peritoneum / drug effects*
  • Peritoneum / pathology
  • Peritonitis / chemically induced*
  • Rats
  • Rats, Sprague-Dawley
  • Zymosan / toxicity*

Substances

  • Complement C1 Inhibitor Protein
  • Fibrin
  • Fibrinogen
  • Zymosan